Am­gen touts its lat­est cut of longterm Repatha da­ta, still hunt­ing elu­sive bil­lions for PC­SK9 fran­chise

It took 5 years for Am­gen to move its PC­SK9 cho­les­terol drug Repatha in­to the block­buster col­umn, all while wag­ing an un­end­ing le­gal war over the patents re­lat­ed to Sanofi and Re­gen­eron’s ri­val. But the Big Phar­ma play­er is still ac­tive­ly pro­mot­ing every new cut of the da­ta in its quest to even­tu­al­ly re­al­ize the big sales rev­enue it al­ways felt would flow from the fran­chise.

This time it’s the 5-year re­sults for its open la­bel Phase II­Is, with more than 85% of the pa­tients achiev­ing an LDL-C lev­el of <40 mg/dL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER